Moreover, a growing body of literature has shown that KPR in in vivo animal studies could be used as complementary medicine for the prevention and treatment of different illnesses, such as myocardial infarction [36], obesity and diabetes [37], arthritis [38], Parkinson’s disease [39], asthma [40,41], thromboembolism [42], osteoporosis [43], etc. These findings are comparable to our findings suggesting that HO-1 expression induced by KPR protects against the ICAM-1 expression induced by LPS. The gene discussed is ICAM1; the disease is asthma.